CLAIMS

1. An antigen binding protein which specifically binds to OSM and which inhibits the binding of OSM to the gp130 receptor but does not directly interact with site II residues and wherein the antigen binding protein comprises CDRH3 of SEQ ID NO: 3 or a variant of SEQ ID NO: 3 wherein Position 98 is substituted for Leu, and wherein the antigen binding protein comprises:
i) CDRH2 as set out in SEQ ID NO: 2
ii) CDRL1 as set out in SEQ ID NO: 4, and
iii) CDRL3 as set out in SEQ ID NO: 6.

2. An antigen binding protein according to claim 1 wherein the antigen binding protein further comprises:
i) CDRH1 as set out in SEQ ID NO: 77, and
ii) CDRL2 as set out in SEQ ID NO: 5 or SEQ ID NO: 78.

3. An antigen binding protein according to any preceding claim wherein the antigen binding protein comprises CDR H3 of SEQ ID NO: 3, CDRH2: SEQ ID NO: 2, CDRL1: SEQ ID NO: 4, and CDRL3: SEQ ID NO: 6.

4. An antigen binding protein according to claim 3 wherein the antigen binding protein further comprises CDR H1 of SEQ ID NO: 77 and CDRL2: SEQ ID NO: 5.

5. An antigen binding protein according to claim 4 wherein the antigen binding protein comprises:
i) CDRH3 as set out in SEQ ID NO: 3;
ii) CDRH1 as set out in SEQ ID NO: 77;
iii) CDRH2 as set out in SEQ ID NO: 2;
iv) CDRL1 as set out in SEQ ID NO: 4;
v) CDRL2 as set out in SEQ ID NO; 5;
vi) CDRL3 as set out in SEQ ID NO: 6; and
vii) the heavy chain framework comprises the following residues:
Position 2 Val, Ile or Gly,
Position 4 Leu or Val
Position 20 Leu, Ile, Met or Val
Position 22 Cys
Position 24 Thr, Ala, Val, Gly or Ser
Position 26 Gly
Position 29 Ile, Phe, Leu or Ser
Position 36 Trp
Position 47 Trp
Position 48 Ile, met, Val or Leu
Position 69 Ile, Leu, Phe, Met or Val

Position 71 Arg
Position 78 Ala, Leu, Val, Tyr or Phe
Position 80 Leu, Met,
Position 90 Tyr or Phe
Position 92 Cys
Position 94 Arg, Lys, Gly, Ser, His or Asn.

6. An antigen binding protein according to any preceding claim wherein the antigen binding protein does not interact directly via CDR H1 or CDR L2 with OSM.

7. An antigen binding protein according to any preceding claim wherein the antigen binding protein comprises a heavy chain variable region encoded by SEQ ID NO:73 and a light chain variable region encoded by SEQ ID NO:71.

8. An antigen binding protein according to any preceding claim wherein the antigen binding protein comprises a heavy chain variable region of SEQ ID NO:74 and a light chain variable region of SEQ ID NO:72.

9. An antigen binding protein according to any preceding claim wherein the antigen binding protein is a humanised antibody.

10. An antigen binding protein according to claim 9 wherein the antibody is IgG1.

11. An antigen binding protein according to any preceding claim wherein the antigen binding protein additionally binds non-human primate OSM.

12. An antigen binding protein according to any one of the preceding claims and wherein the antigen binding protein binds OSM with an affinity of less than 40pm.

13. An antigen binding protein according to any preceding claim wherein the antigen binding protein does not compete with an antibody which has a heavy chain of SEQ ID NO:79 and a light chain of SEQ ID NO: 80 in a competition ELISA assay.

14. An antigen binding protein according to claim 1 wherein the antigen binding protein binds to both Marmoset and human OSM with an affinity stronger than 1nM when measured by Biacore or kinexa.

15. A pharmaceutical composition comprising an antigen binding protein according to any preceding claim and a pharmaceutically acceptable carrier.

16. Use of the composition of claim 15 in the manufacture of a medicament for treating a human patient afflicted with an inflammatory disorder or disease.

17. Use of the composition of claim 15 in the manufacture of a medicament for treating a human patient afflicted with an inflammatory arthropathy, rheumatoid arthritis, osteoarthritis, idiopathic pulmonary fibrosis (IPF), Systemic sclerosis, Sjogrens syndrome, Scleroderma and/or psoriasis.